Last reviewed · How we verify
Venetoclax Oral Tablet
At a glance
| Generic name | Venetoclax Oral Tablet |
|---|---|
| Also known as | Venetoclax, venetoclax plus azacytidine, Cytarabin |
| Sponsor | Montefiore Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm (PHASE2)
- An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial (PHASE3)
- Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) (PHASE1, PHASE2)
- CIML NK Cells With Venetoclax for AML (PHASE1)
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) (PHASE2, PHASE3)
- A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). (PHASE3)
- A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (PHASE2)
- Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Venetoclax Oral Tablet CI brief — competitive landscape report
- Venetoclax Oral Tablet updates RSS · CI watch RSS
- Montefiore Medical Center portfolio CI